mRNA Nanotech Nightmare: Long-Term Study Uncovers Bizarre Vaccine Phenomena
Scientists watched for a year as vaccine samples transformed before their eyes.
A groundbreaking new study published in the International Journal of Vaccine Theory, Practice, and Research has uncovered disturbing evidence of self-assembling nanostructures in the Pfizer and Moderna COVID-19 mRNA vaccines. Titled, Real-Time Self-Assembly of Stereomicroscopically Visible Artificial Constructions in Incubated Specimens of mRNA Products Mainly from Pfizer and Moderna: A Comprehensive Longitudinal Study, the comprehensive study, conducted by researchers Young Mi Lee and Daniel Broudy, used stereomicroscopic examination to analyze vaccine samples over an extended period.1
Key Findings
The researchers observed "numerous -- on the order of 3~4 x 106 per milliliter of the injectable -- visible artificial self-assembling entities ranging from about 1 to 100 μm, or greater, of many different shapes." These included "animated worm-like entities, discs, chains, spirals, tubes, right-angle structures containing other artificial entities within them, and so forth."1
Perhaps most alarmingly, the study found that "As time progressed during incubation, simple one- and two-dimensional structures over two or three weeks became more complex in shape and size developing into stereoscopically visible entities in three-dimensions. They resembled carbon nanotube filaments, ribbons, and tapes, some appearing as transparent, thin, flat membranes, and others as three-dimensional spirals, and beaded chains."1
The researchers concluded that "Our observations suggest the presence of some kind of nanotechnology in the COVID-19 injectables."1
Implications for Vaccine Safety
The study raises serious questions about the true contents and safety profile of the mRNA vaccines. As the authors note, "All these are exceedingly beyond any expected and acceptable levels of contamination of the COVID-19 injectables."1
The presence of self-assembling nanostructures, if confirmed by further research, could explain many of the unexpected adverse events reported following COVID-19 vaccination. The study observed that these structures exhibited "unique striated curled ribbons and various filaments, scaled like snakeskin, that seemed to contain hollow compartments as in bamboo shedding bubbles."1
The researchers also found evidence that electromagnetic fields could stimulate or alter these nanostructures, noting "When in close proximity to an electromagnetic field, the filaments could possibly trigger the formation of a clot and, thus, disturb free blood or lymph flow."1
Self-Amplifying mRNA Technologies
It's important to note that the field of mRNA vaccine technology is rapidly evolving. Recently, the first self-amplifying mRNA vaccine was approved in Japan.2 This technology, developed by CSL and Arcturus, uses mRNA that codes for replicase proteins to produce more copies of itself once inside cells.2 While this approach aims to enhance vaccine efficacy and potentially reduce dosage requirements, it also raises new questions about the long-term effects and potential risks of such self-replicating technologies in the human body.
The approval of self-amplifying mRNA vaccines adds another layer of complexity to the findings of Lee and Broudy's study. If self-assembling nanostructures are indeed present in current mRNA vaccines, how might they interact with self-amplifying mRNA technologies? This question underscores the urgent need for further research and transparency in vaccine development.
Call for Further Investigation
This study represents a significant challenge to the publicly disclosed ingredients of the mRNA vaccines. As the authors state, "The fact that such nanotechnology is in the COVID-19 injectables was first discussed, we believe, by Campra and colleagues (2021a, 2021b; Spectroscopy & Campra, 2021). They used much more powerful spectroscopic methods and equipment revealing what appeared to be programmable entities at the nano-level."1
The implications of these findings, if independently verified, are profound. They suggest an urgent need for a thorough re-evaluation of the mRNA vaccine technology and its potential long-term effects on human health. As the study concludes, "until the components can be verified and their long-term effects understood, a necessity flouted by calls for Emergency Use Authorization, an immediate global ban is needed."1
This groundbreaking research demands immediate attention from the scientific community, regulatory bodies, and the public at large. The potential presence of undisclosed, self-assembling nanotechnology in vaccines administered to billions of people worldwide represents a matter of utmost concern for public health and medical ethics.
References
1 Lee, Y. M., & Broudy, D. (2024). Real-Time Self-Assembly of Stereomicroscopically Visible Artificial Constructions in Incubated Specimens of mRNA Products Mainly from Pfizer and Moderna: A Comprehensive Longitudinal Study. International Journal of Vaccine Theory, Practice, and Research, 3(2), 1180-1244.
2 Lowe, D. (2024). The First Self-Amplifying mRNA Vaccine. Science.org.
'Really Chilling': Five Countries to Test European Vaccination Card
Originally published on www.childrenshealthdefense.org by Michael Nevradakis, Ph.D.
Belgium, Germany, Greece, Latvia and Portugal will test the new vaccination card in a variety of formats, including printed cards, mailed copies and digital versions for smartphones. Critics called it a "direct threat to freedom."
Five European Union (EU) countries in September will pilot the newly developed European Vaccination Card (EVC), which "aims to empower individuals by consolidating all their vaccination data in one easily accessible location.
The pilot program marks a step toward the continent-wide rollout of the card, according to Vaccines Today.
Belgium, Germany, Greece, Latvia and Portugal will test the new card in a variety of formats, including printed cards, mailed copies and digital versions for smartphones.
The program aims to "pave the way for other countries by harmonising vaccine terminology, developing a common syntax, ensuring adaptability across different healthcare settings, and refining EVC implementation plans," Vaccines Today reported.
The plans will be made public in 2026, "extending the EVC system beyond the pilot phases and enabling broad adoption across all EU Member States."
According to Vaccines Today, the EVC program seeks to leverage "the lessons learned from the COVID-19 pandemic" and foster "innovation in vaccination management," with the goal of "taking crucial steps toward a more resilient and health-secure future."
The EVC is based on the World Health Organization's (WHO) Global Digital Health Certification Network (GDHCN). The EU and WHO co-launched the GDHCN in June 2023 to promote a global interoperable digital vaccine passport, based on the EU's digital health certificate launched during the pandemic.
Vaccines Today described the GDHCN as a "citizen-centered method of storing and sharing data," rather than a system that relies "solely on public health systems."
Greece was the first European country to propose the implementation of a vaccination passport, which was eventually adopted as the EU's "Green Pass." Greece later became the first EU member state to adopt a digital "Covid passport."
Greece's University of Crete is coordinating the EVC project alongside 14 partners from nine countries -- and with 6.75 million euros ($7.3 million) in funding from the European Commission's (EC) EU4Health program. The EC is the EU's executive branch.
'Direct threat to our freedom'
Experts who spoke with The Defender said that plans for the EVC pose a direct threat to personal and health freedom and national sovereignty.
Dr. David Bell, a public health physician, biotech consultant and former director of Global Health Technologies at Intellectual Ventures Global Good Fund, said:
"The proposed vaccination card reflects an increasing effort to utilize public health tools as a means to concentrate wealth and provide a means to control populations. It is very reminiscent of approaches in parts of Europe pre-World War II, and essentially serves a similar purpose: to exclude individuals who do not follow government instructions from society.
"The trial in Europe is an obvious next step after the recent widening of surveillance under the IHR [International Health Regulation] amendments, which greatly increase the likelihood of recurrent lockdowns to enable mandated vaccination as a way to force mass use, and profit-making, from vaccines."
Dutch attorney Meike Terhorst also criticized the pilot program, calling a digital vaccination passport a "direct threat to our freedom and also the sovereignty of any state."
"All our powers are handed over to the globalists, the group of bankers and investors," Terhorst said.
Catherine Austin Fitts, founder and publisher of the Solari Report and former U.S. assistant secretary of Housing and Urban Development, said plans for the EVC represent "another step toward asserting control of labor and travel, with a goal to controlling resources and assets."
Fitts said:
"The goal is financial control. There is no legitimate public health purpose. The central bankers are hiding behind a health narrative -- policies like lockdown are a way to manage inflation and resource demand when monetary policy is highly inflationary."
Experts also tied the rollout of the EVC to warnings from government and health officials about the "next pandemic," potentially caused by the bird flu or a still-unknown "Disease X."
According to Fitts:
"Many steps are underway to prepare for a bird flu pandemic. Chicken is the most significant source of meat protein.
"So far in response to the current bird flu claims, I am told by experts who follow bird flu claims that 99 million birds have been killed in the U.S. and 500 million worldwide. Bird flu vaccines have been shipped to Europe. A vaccine card can be used to try to pressure or force people to take another unnecessary injection."
French science journalist and author Xavier Bazin told The Defender, "For the time being, a vaccination card in Europe is meant to ensure that most children get their vaccination." However, he said he believes the next step is to try to mandate the measles, mumps and rubella (MMR) vaccine across Europe.
"Even if they do not succeed with MMR, this kind of card will be perfect when the next 'pandemic' hits and they want to mandate an emergency vaccine, like they did with COVID," Bazin said.
Similarly, Bell said:
"WHO and other agencies are clear in their intent to link compliance with centralized health dictates with the ability of people to go about their daily life.
"Whilst directly against post-WWII conventions, including the Universal Declaration of Human Rights and the spirit of the Nuremberg Declaration, they have the backing of major international agencies and the corporate interests that have become enmeshed with them over the past two decades."
Experts also pointed out that plans for the EVC have been in the works even before the COVID-19 pandemic.
"The digital vaccination passport is a technical means to override personal freedoms, such as the right to say no to a vaccination," Terhorst said. "It is a means to turn free human beings into 'slaves.' This digital vaccination passport has been planned many years in advance by the globalists."
Plans for EU vaccination card began in 2018
Development of the EVC began in 2018, according to official EU documents.
That year, Gavi, the Vaccine Alliance announced at the annual meeting of the World Economic Forum (WEF), that it would become the first international nonprofit to partner with the WEF's Center for the Fourth Industrial Revolution.
"In my opinion, [the EVC] is linked to Gavi's project of mixing digital ID and vaccination proof," Bazin said.
In 2019, the ID2020 Alliance, along with Gavi and the Government of Bangladesh, announced a new digital ID program, for which it was later announced that it aimed "to provide biometric-linked digital IDs to infants when they receive routine immunisations."
The Bill & Melinda Gates Foundation is a partner of Gavi, which, in turn, closely collaborates with the ID2020 Alliance, which has promoted the development of digital ID.
According to Vaccines Today, the EVC is necessary because zoonotic diseases -- those transmitted from animals to humans -- "continue to pose a significant threat to global health."
"As Europe transitions from emergency measures to long-term COVID-19 management, there is a critical opportunity to strengthen resilience and increase preparedness for future health threats," Vaccines Today reported, citing the EVC as one such project.
Other EU-level projects in the works, according to Vaccines Today, include "a clinical decision system that provides vaccination recommendations, a screening tool to identify and invite vulnerable populations, an electronic Product Information Leaflet (e-PIL) to enable the transfer of vaccines across countries without having to repackage them, and a modeling and forecasting tool to assess the impact of public health interventions."
But for Bazin, such efforts have little to do with protecting public health.
"For those who think vaccination is a medical procedure that should always remain a free choice, the European Vaccination Card is really chilling and should be opposed," he said.
HHS 'Declaration of Emergency' for Bird Flu Paves Way for PCR Testing and More EUA Vaccines, Critics Say
Originally published on www.childrenshealthdefense.org by Brenda Baletti, Ph.D.
Public health authorities have taken a series of actions in recent weeks to facilitate the possible future distribution of bird flu testing and vaccines, even as the CDC maintains the current public health risk from bird flu is low.
The U.S. Department of Health and Human Services (HHS) this month issued a declaration of emergency, announcing that some flu viruses -- including H5N1 bird flu -- could cause a pandemic and threaten national security.
The announcement by HHS Secretary Xavier Becerra amended a 2013 section of the Federal Food, Drug, and Cosmetic (FD&C) Act, which allows the agency to extend the availability of medical countermeasures to pandemic influenza A viruses, including the currently circulating H5N1 strain of bird flu.
Prior to the amendment, the declaration covered only the previous H7N9 strain of bird flu.
The announcement specified that current circumstances justify the emergency use authorization (EUA) of in vitro diagnostics such as RT-PCR tests to detect bird flu and other pandemic influenza A viruses.
"This paves the way for more EUA vaccines, devices and products to possibly be effective against these new and unknown viruses," attorney Ray Flores told The Defender.
He added:
"Just as EUA PCR tests exaggerated the COVID-19 pandemic, the detection of avian influenza and influenza A viruses with pandemic potential via unlicensed PCR tests is destined to justify lockdowns, masking, invasive nasal swabs, and wide-scale vaccination with experimental mRNA technology.
"The stage is set for RT-PCR tests to take the pivotal role of determining false positives with amped up cycle thresholds designed to declare asymptomatic, otherwise healthy people to be infected -- just like last time."
Under the FD&C Act, HHS can take steps to facilitate countermeasures only after the secretary of either the U.S. Department of Homeland Security, U.S. Department of Defense or HHS determines there is an emergency or potential for an emergency involving a chemical, biological, radiological or nuclear agent that may threaten the national or health security of U.S. citizens.
After that determination, the HHS secretary can declare that existing circumstances justify an EUA that would allow the FDA to authorize previously unlicensed drugs or vaccines or previously unapproved uses of licensed drugs.
The amendment covers animal or human flu viruses -- circulating in wild birds, humans, or domestic animals -- that may infect humans, may have caused pandemics in the past or may mutate to cause a pandemic in humans for which they have no prior immunity.
Becerra said in the amendment that the bird flu viruses may pose a public health threat, despite acknowledging that it "may initially only be occasionally transmitted to or between humans." However, he added that bird flu viruses may "have the potential to become highly transmissible in humans and can cause significant morbidity and mortality."
The currently circulating H5N1 virus is one in a series of bird flu viruses that pose such a threat, although the virus is not easily transmissible to humans and none of the human cases reported to the Centers for Disease Control and Prevention (CDC) involved severe disease, the announcement said.
"We cannot be sure," Becerra said, that the mild cases associated with dairy cattle represent the full spectrum of the disease, "nor can we be assured that the virus will not mutate to cause more severe disease and/or to become more transmissible."
The CDC reports the current public health risk is low and that surveillance shows "no indicators of unusual influenza activity in people, including avian influenza A(H5)."
There have been a total of 14 reported human cases since 2022, according to the agency. Four occurred after exposure to dairy cows, 10 after exposure to poultry and none have been serious.
AMA updates vaccine codes for potential EUA vaccine
The day after Becerra's announcement, on July 19, the American Medical Association (AMA) announced an update to its Current Procedural Terminology (CPT) codes to include a new code for bird flu vaccines, should they receive EUA from the FDA.
CPT codes are used by providers to report healthcare procedures and services and to update medical records.
The AMA said it is publishing the code update now "to ensure electronic systems across the U.S. health care system are prepared in advance for the potential FDA authorization."
The update included new codes for administering the potential bird flu vaccine to both children and adults.
The new code is for a cell-culture-derived vaccine adjuvanted for intramuscular use, which refers to an inactivated flu virus grown in cultured mammalian cells.
Cell-culture vaccines are a newer technology developed to replace the traditional egg-based vaccine production for flu vaccines. It is said to be cleaner, faster and more scalable than its predecessor.
Vaccine producer contracted to produce millions of doses of bird flu vaccines
The creation of the codes also follows an agreement, announced May 30, between the U.S. government and CSL Seqirus -- one of the largest vaccine producers in the world -- to complete 4.8 million doses of a "pre-pandemic vaccine that is well-matched to the H5 of the currently circulating H5N1 strain," as part of the U.S. National Pre-Pandemic Influenza Vaccine Stockpile program.
HHS Assistant Secretary for Preparedness and Response Dawn O'Connell told reporters some of those shots could be available as early as this month, Reuters reported.
This was the fourth contract awarded to CSL Seqirus under a multi-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), which largely pays for the vaccines.
Marc Lacey, CSL Seqirus global executive director for the pandemic, said in the press release that the CDC maintains that bird flu poses a low risk to public health. However, "This agreement, building upon prior agreements with BARDA, will help support the U.S. government's ability to respond swiftly in the event that the current avian flu situation changes."
Seqirus manufactures the vaccines in Holly Springs, North Carolina, at a $1 billion facility built in 2009 and opened in 2013 through a partnership between Novartis and BARDA that was in part facilitated by grants and tax incentives from local government.
CSL Seqirus' parent company acquired Novartis' facility in 2014.
The facility is the largest producer of cell-based vaccines in the world, with the capacity to deliver up to 150 million flu vaccines within six months of an emergency pandemic declaration. Then it could continue to produce large quantities of vaccines.
Their massive vaccine production capacity, the company said, is dependent on continued research and development along with seasonal vaccine manufacturing, which provides a "warm base" for pandemic production. That means the production of seasonal vaccines makes it possible for the company to maintain the materials and personnel necessary to produce massive vaccine quantities.
CSL Seqirus' H5N8 avian influenza vaccine received the European Union's marketing authorization in April. The vaccine requires a two-dose series, with the second dose administered at least three weeks after the first.
The European Commission Health Emergency Preparedness and Response (HERA) program in June announced the purchase of 665,000 doses of CSL Seqirus' H5N8 avian influenza vaccine, with an option to acquire another 40 million doses over the next four years.
Finland already plans to offer the CSL Seqirus H5N8 bird flu vaccine to approximately 10,000 people deemed at high risk of exposure to the virus.
WHO announces project to fast-track mRNA bird flu vaccines
The World Health Organization (WHO) today announced a new project to speed up the "development and accessibility" of an mRNA bird flu vaccine for manufacturers in low- and middle-income countries as part of the mRNA Technology Transfer Programme.
The same program was used to help develop and transfer the mRNA platform for COVID-19 to the developing world.
Earlier this month, BARDA awarded $176 million to Moderna to develop and test its pre-pandemic mRNA vaccine against H5N1.
Late-stage testing would begin in 2025, pending results from the Phase 1/2 trial of five different mRNA vaccine options testing on about 1,500 people that concluded last week.
The contract includes options to speed up the development timeline if there is an increase in the number of human cases, the severity of the virus or if human-to-human transmission becomes possible, Reuters reported.
The U.S. government is also in talks with Pfizer about possibly supporting its development of an mRNA vaccine targeting the H5 family of bird flu viruses, according to the Financial Times.
'Mock-up' vaccines allow industry to roll out experimental shots with little testing
Becerra's declaration offered a brief overview of previous bird flu viruses that threatened public health, citing the 2009 A/H1N1 influenza pandemic and the H7N9, in 2013-2014.
High mortality rates allegedly associated with these strains were offered as justification for concern that although the current bird flu strain does not easily transmit to humans and is not particularly virulent, it could become so.
Discussing this hypothesis and the possible reasons behind it with Children's Health Defense (CHD) Chief Scientific Officer Brian Hooker, Ph.D., on a recent episode of his CHD.TV show "Doctors & Scientists," internist Dr. Meryl Nass said:
"The people who make their money by warning us about pandemics, by selling pandemic products, people who get promotions because they have developed pandemic vaccines or been involved in some way in tests or other, the pandemic industry has been very interested for over 20 years in figuring out ways to give experimental vaccines that they develop very quickly to an entire population without having to test them. Because if you test them, it takes months longer before you can give them out, and your pandemic is likely to be over at that point.
"You need to roll them out fast if you're going to use them. And if you're going to cause a nation to spend millions or billions of dollars buying them, you're going to have to come up with them quickly."
Nass explained how the industry can quickly create and roll out new pandemic vaccines in the U.S. by creating "mock-up" vaccines that are later used as platforms for new vaccines. Drugmakers use existing vaccines as substrates and can insert new antigens into them when a new virus strain appears in what Nass called a "plug and play" approach to making new vaccines.
Nass reviewed the three currently approved bird flu vaccines, raising serious questions about the small size of the clinical trials and serious adverse events in the trials, including fatalities.
For example, she said, Sanofi Pasteur's bird flu vaccine was licensed in 2007 for the national stockpile based on a clinical trial of only 103 subjects. One of those subjects died and three others experienced a serious adverse event, including cancer.
In trials for GSK's vaccine, licensed in 2013, 0.5% of subjects experienced serious adverse events, including thyroid cancer and cerebral vascular events. In the trials for Audenz, CSL Seqirus' H5N1 vaccine, serious adverse events occurred in all age groups, including deaths in older adults.
These vaccines, she said, are prototypes for vaccines that could be emergency authorized for the current virus.
According to Nass, the media are telling people -- referring to a May 2024 article in The Guardian -- "the only question is when do we pull the trigger on these vaccines?"Nass added that the U.S. government in May relaxed the rules for handling bird viruses so they could be examined in regular hospital labs rather than high-security labs.
"So the U.S. government is trying to imply that this is a deadly virus, but they're acknowledging it is basically a nothing burger virus for humans at this time," she said.
However, she warned, the vaccines themselves could be dangerous.
No hay comentarios:
Publicar un comentario